Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00852852 · ClinicalTrials.gov registry record · NA
Computerized Assessment for Patients With Cancer
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 779
- Enrollment target
NCT00852852: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT00852852 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 779 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00852852, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 779 participants
- Enrollment target
Study Summary
This research study will test a new online computer program for patients, the Electronic Self-Report Assessment-Cancer (ESRA-C 2). The program allows patients to report symptoms and quality of life issues and learn information about how to deal with these experiences. The computer program is being tested to see if it can improve communications between patients and their care team and if it can improve patients' experiences during and after treatment.
Interventions
- BEHAVIORAL Electronic Self-Report Assessment - Cancer (ESRA-C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 779 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-12 |
| Phase | NA |
What the finished NCT00852852 record still lists
NCT00852852 is an interventional study that assigns participants to a tested intervention. The registered 779 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which Electronic Self-Report Assessment - Cancer (ESRA-C) is the first listed.
NCT00852852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00852852 about?
NCT00852852 is a clinical study titled "Computerized Assessment for Patients With Cancer". This research study will test a new online computer program for patients, the Electronic Self-Report Assessment-Cancer (ESRA-C 2). The program allows patients to report symptoms and quality of life issues and learn information about how to deal with these experiences. The computer program is being t...
What is the current status of trial NCT00852852?
This trial is currently completed. It is a NA study. The enrollment target is 779 participants. The study started on 2008-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00852852?
The interventions under investigation include: Electronic Self-Report Assessment - Cancer (ESRA-C) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00852852?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00852852's enrollment target sits among peer trials
779 142nd of 2000 higher than 1,859 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia